高复发及浸润性膀胱癌的分子生物学基础  

Astudy of gene alteration and its biological significance on theinvasiveness and recurrency of bladder can cer

作　　者：郭德荣[1] 顾方六[1] 蔡碧娟[1] 周爱儒[2] 

机构地区：[1]北京医科大学泌尿外科研究所 [2]北京医科大学生化教研室,100034

出　　处：《中华泌尿外科杂志》1999年第9期539-541,共3页Chinese Journal of Urology

基　　金：卫生部科学研究基金

摘　　要：目的　探讨膀胱癌多发，复发和浸润的分子生物学基础。　方法　采用分子生物学方法对膀胱癌实体肿瘤 Ｔ Ｇ Ｆα， Ｅ Ｇ Ｆ Ｒ，ｐ１６ 和ｐ５３ 基因表达、缺失及生物学意义进行了研究。　结果　３４ 例膀胱癌中８５ ％ （２９／３４） Ｔ Ｇ Ｆαｍ Ｒ Ｎ Ａ 阳性表达，肿瘤的表达量是癌旁正常对照的２ ～５ 倍， Ｐ＜０ ．０１ 。膀胱癌 Ｅ Ｇ Ｆ Ｒ ｍ Ｒ Ｎ Ａ 表达率为４４ ％ （４／９） 。５０ 例膀胱癌ｐ５３ 蛋白免疫组化阳性核染率４２ ％（２１／５０ ） ，其中 Ｐ Ｔ３ ８２ ％ （９／１１） ， Ｇ３ ７２ ％ （１３／１７） ， Ｐ Ｔ２ ４０ ％ （１２／３０） ， Ｇ２ ３２ ％ （８／２５） ， Ｐ Ｔ１ 和 Ｇ１ 级肿瘤未见阳性核染。随访２５ 例，ｐ５３ 阳性核染者中７６ ％ （１０／１３） 有复发转移。２０ ％ （２／１０） 实体膀胱癌有ｐ１６ 基因的丢失。结论　 Ｔ Ｇ Ｆαｍ Ｒ Ｎ Ａ 高表达可能是膀胱癌发生的早期事件。 Ｅ Ｇ Ｆ Ｒ 和ｐ５３ 基因异常表达可能与膀胱癌的分化和恶性度相关。Objective To investigate the cause of multiplicity ,recurrency andinvasiveness of bladdercancer on biological basis . Methods The expression or deletion of T G F, E G F R,p16 and p53 were stu died in the tum or mass of bladder cancer and their biologicalsignificance was probed into . Results T G Fαm R N A was positively expressed in 29 ofthe 34 bladder cancer (85 % ) and quantitatively being 2 ～5 tim esofthatin the para cancer tissues ( P< 0 .01) . E G F R m R N A was positively expressed in 4 of 9 (44 % ) . In50 cases of bladder cancer ,the nuclear staining rate of p53 protein by m eans of im m unohistochemical tech nique was 42 % (21/50) ,among w hich P T3 being 82 % (9/11) , G3 72 % (13/17) , P T2 40 % (12/30) and G2 32 % (8/25) . No nuclear staining has been observed in P T1 and G1 tu mors.25 patients have been fol lowed up . Recurrence and m etastasis occurred in 10 of 13 patients with positive p53 nuclearstaining . In 2 of10 cases,there was deletion of p16 in the tum or mass of the bladder cancer . Conclusions High T G Fαm R N Aexpression might be an early eventin the develop ment of bladder cancer while abnorm al expressionof E G F Rand p53 genes might be related to the differentiation and malignancy of bladder cancer .

关 键 词：膀胱肿瘤 膀胱癌 分子生物学 复发 浸润性 

分 类 号：R737.14[医药卫生—肿瘤]